Travel Vaccines Market Scope
Travel vaccines protect travelers from serious diseases. The travel vaccines market is expected to grow in the future due to the increasing number of travelers throughout the globe. Increasing incidence of travel-related diseases and government initiatives to ensure travel safety boosting the demand for travel vaccines. Rising investments towards the research and development of more effective vaccines provide new growth opportunities in the near future.
The market study is being classified by Type (Hepatitis B Vaccines, Hepatitis A Vaccines, Typhoid and paratyphoid fever., Meningococcal Vaccines and Others), by Application (Domestic Travel and Outbound Travel) and major geographies with country level break-up.
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Travel Vaccines market throughout the predicted period.
Pfizer Inc. (United States), Sanofi S.A (France), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AstraZeneca plc (United Kingdom), Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Bausch Health Companies Inc. (Canada), SK Chemicals (South Korea) and Bavarian Nordic (Denmark) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Hualan Biological Engineering Inc. (China) and Serum Institute of India (India).
AdvanceMarketAnalytics has segmented the market of Global Travel Vaccines market by Type, Application and Region.
On the basis of geography, the market of Travel Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In Oct 2019, Bavarian Nordic announced that it has entered an agreement with GlaxoSmithKline plc to acquire the manufacturing and global rights to Rabipur®/RabAvert® and Encepur®. Rabipur/RabAvert provides pre- and post-exposure protection against rabies, while Encepur protects against European (Western) tick-borne encephalitis (TBE) virus.
In Dec 2018, The U.S. Food and Drug Administration has approved VAXELIS(TM) for use in children from 6 weeks through 4 years of age (prior to the 5th birthday). VAXELIS was developed as part of a joint-partnership between Sanofi and MSD.
- Governments Initiatives to Ensure Travel Safety
- Increasing Incidence of Travel-Related Diseases
- Increasing Number of Travelers throughout the Globe
- Rising Prevalence of Infectious Diseases
- Rising Investments towards the Research and Development for More Effective Vaccines
- Growth in Tourism Industry in Developing Countries
- Travel Vaccines are Expensive
- Longer Timelines Required for Vaccine Production
- Stringent Government Regulation
Key Target AudienceTravel Vaccines Manufacturer, Travel Vaccines Suppliers/Distributors, Raw Material Suppliers, Pharmaceutical Industry, Potential Investors and Research and Development Firm
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase